CVKD — CADRENAL THERAPEUTICS INC
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Fundamentals (SEC EDGAR XBRL)
Financials from SEC company facts, point-in-time aligned to each figure’s EDGAR filing date.
| Revenue TTM | Revenue YoY | Net income TTM | Net income YoY | ROE (TTM) | Gross margin | Net margin | P/E (TTM) | P/E pct | P/B | P/B pct |
|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — |
Wall Street Analyst Consensus
Ratings, 12-month price target and EPS forecasts from the Nasdaq public analyst feed. · Fetched 2026-11-19
| Fiscal quarter end | Consensus EPS forecast | Forward P/E | High EPS | Low EPS | # estimates | Revisions (4wk up/down) |
|---|---|---|---|---|---|---|
| Dec 2026 | -0.86 | — | -0.82 | -0.89 | 3 | — |
| Mar 2027 | -0.88 | — | -0.88 | -0.88 | 1 | — |
| Jun 2027 | -0.90 | — | -0.90 | -0.90 | 1 | — |
| Sep 2027 | -0.93 | — | -0.93 | -0.93 | 1 | — |
| Dec 2027 | -0.92 | — | -0.92 | -0.92 | 1 | — |
| Fiscal year end | Consensus EPS forecast | Forward P/E | High EPS | Low EPS | # estimates | Revisions (4wk up/down) |
|---|---|---|---|---|---|---|
| Dec 2026 | -3.86 | — | -3.76 | -3.92 | 3 | — |
| Dec 2027 | -3.01 | — | -2.21 | -3.55 | 3 | — |
| Dec 2028 | -1.85 | — | -1.78 | -1.92 | 2 | — |
Forward P/E uses the fetch-time price divided by consensus EPS (quarter annualised ×4). Revision score = (upgrades − downgrades) / estimates, from Nasdaq 4-week counts. Source: Nasdaq analyst data
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
As of Q3 2026, 26 SEC-registered investment managers reported holding CVKD (CADRENAL THERAPEUTICS INC) in their latest 13F filings, with a combined reported value of $218.91K across 202.81K shares. That is -11.9% by share count (-13.46K shares) versus the previous quarter, while reported value moved -71.6%. Ownership is concentrated: the five largest holders account for 64.4% of reported value and the top ten for 89.9%.
Compared with the prior quarter, 7 opened new positions, 5 added to existing stakes, 1 trimmed, 3 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q3 2026, not real-time trading.
Major shareholders of CADRENAL THERAPEUTICS INC (CVKD) include ARMISTICE CAPITAL, LLC, Vanguard Group, Citadel Advisors, ranked by reported 13F value among the 51 institutional holders on this page.
CVKD is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 26 | 202.81K | $218.91K | -11.9% |
| Q2 2026 | 22 | 132.89K | $443.81K | +6.5% |
| Q1 2026 | 20 | 91.07K | $460.10K | +22.4% |
| Q4 2025 | 19 | 96.36K | $653.35K | +1.7% |
| Q3 2025 | 20 | 114.24K | $1.57M | +8.9% |
| Q2 2025 | 17 | 68.40K | $823.91K | -9.0% |
| Q1 2025 | 16 | 69.35K | $1.22M | +60.8% |
| Q4 2024 | 10 | 14.87K | $215.47K | +100.0% |
Over the 8 quarters shown, institutional share counts increased 1264% in aggregate (Q4 2024 → Q3 2026); the largest single-quarter swing was Q4 2024 (+100.0%).
Top Institutional Holders (Q3 2026) — 25 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 39.67K | $42.85K | 0.01% | New | |
| 35.38K | $38.00K | 0.00% | Add | |
| 19.84K | $21.42K | 0.01% | New | |
| 18.96K | $20.47K | 0.00% | Hold | |
| 16.86K | $18.21K | 0.00% | Reduce | |
| 13.72K | $14.82K | 0.00% | New | |
| 12.36K | $13.35K | 0.00% | New | |
| 10.10K | $10.91K | 0.00% | New | |
| 8.31K | $8.98K | 0.00% | Hold | |
| 7.24K | $7.89K | 0.00% | New | |
| 5.86K | $6.33K | 0.00% | Add | |
| 4.63K | $5.00K | 0.00% | Add | |
| 3.89K | $4.20K | 0.00% | Add | |
| 2.97K | $3.21K | 0.00% | Add | |
| 1.00K | $1.08K | 0.00% | Hold | |
| 704 | $760 | 0.00% | Hold | |
| 380 | $410 | 0.00% | Hold | |
| 300 | $324 | 0.00% | Hold | |
| 200 | $230 | 0.00% | New | |
| 150 | $162 | 0.00% | Hold | |
| 100 | $108 | 0.00% | Hold | |
| 99 | $107 | 0.00% | Hold | |
| 35 | $38 | 0.00% | Hold | |
| 30 | $32 | 0.00% | Hold | |
| 25 | $27 | 0.00% | Hold |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 22 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 50.14K | $167.46K | 0.00% | Add | |
| 29.05K | $97.00K | 0.00% | New | |
| 19.02K | $63.54K | 0.00% | New | |
| 19.02K | $63.54K | 0.00% | Reduce | |
| 8.31K | $27.76K | 0.00% | Hold | |
| 1.28K | $4.29K | 0.00% | New | |
| 1.28K | $4.28K | 0.00% | Add | |
| 1.11K | $3.71K | 0.00% | Add | |
| 1.00K | $3.34K | 0.00% | New | |
| 706 | $2.36K | 0.00% | Add | |
| 650 | $2.17K | 0.00% | New | |
| 380 | $1.27K | 0.00% | New | |
| 300 | $1.00K | 0.00% | Hold | |
| 150 | $501 | 0.00% | Hold | |
| 100 | $334 | 0.00% | New | |
| 99 | $331 | 0.00% | Hold | |
| 93 | $311 | 0.00% | New | |
| 86 | $287 | 0.00% | New | |
| 35 | $117 | 0.00% | Hold | |
| 30 | $100 | 0.00% | Hold | |
| 25 | $84 | 0.00% | Hold | |
| 5 | $17 | 0.00% | Hold |
Q1 2026 — 20 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 45.20K | $231.43K | 0.00% | New | |
| 21.63K | $110.72K | 0.00% | Add | |
| 8.31K | $42.55K | 0.00% | New | |
| 7.50K | $31.88K | 0.00% | Hold | |
| 5.50K | $28.14K | 0.00% | Add | |
| 1.49K | $8.00K | 0.01% | New | |
| 393 | $2.01K | 0.00% | Reduce | |
| 300 | $1.54K | 0.00% | Reduce | |
| 200 | $1.02K | 0.00% | New | |
| 150 | $768 | 0.00% | Reduce | |
| 100 | $512 | 0.00% | Reduce | |
| 100 | $512 | 0.00% | Hold | |
| 99 | $507 | 0.00% | Hold | |
| 35 | $179 | 0.00% | Hold | |
| 30 | $154 | 0.00% | Hold | |
| 25 | $123 | 0.00% | Hold | |
| 5 | $26 | 0.00% | Hold | |
| 3 | $15 | 0.00% | Reduce | |
| 1 | $5 | 0.00% | New | |
| 1 | $5 | 0.00% | Hold |
Q4 2025 — 19 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 53.91K | $365.52K | 0.00% | Reduce | |
| 14.53K | $98.50K | 0.00% | Add | |
| 13.00K | $88.14K | 0.00% | Reduce | |
| 7.50K | $50.85K | 0.00% | Hold | |
| 3.52K | $23.88K | 0.00% | Add | |
| 1.08K | $7.32K | 0.00% | Add | |
| 1.04K | $7.08K | 0.00% | Add | |
| 532 | $3.61K | 0.00% | New | |
| 500 | $3.39K | 0.00% | Hold | |
| 300 | $2.03K | 0.00% | Hold | |
| 150 | $1.02K | 0.00% | Hold | |
| 100 | $678 | 0.00% | Hold | |
| 99 | $671 | 0.00% | Hold | |
| 35 | $237 | 0.00% | Hold | |
| 30 | $203 | 0.00% | Hold | |
| 25 | $170 | 0.00% | Hold | |
| 5 | $34 | 0.00% | Hold | |
| 1 | $7 | 0.00% | Hold | |
| 1 | $7 | 0.00% | New |
Q3 2025 — 20 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 54.24K | $747.14K | 0.00% | Add | |
| 19.86K | $273.63K | 0.00% | New | |
| 14.20K | $196.39K | 0.00% | New | |
| 12.71K | $175.08K | 0.00% | Hold | |
| 7.50K | $103.31K | 0.00% | New | |
| 3.38K | $46.72K | 0.00% | Add | |
| 880 | $12.17K | 0.00% | Add | |
| 500 | $6.48K | 0.00% | Hold | |
| 300 | $4.15K | 0.00% | New | |
| 172 | $2.41K | 0.00% | Hold | |
| 150 | $2.08K | 0.00% | New | |
| 100 | $1.38K | 0.00% | Hold | |
| 99 | $1.37K | 0.00% | Reduce | |
| 35 | $484 | 0.00% | Reduce | |
| 35 | $484 | 0.00% | Hold | |
| 30 | $415 | 0.00% | Hold | |
| 25 | $346 | 0.00% | Hold | |
| 20 | $277 | 0.00% | Hold | |
| 5 | $69 | 0.00% | Hold | |
| 1 | $14 | 0.00% | Reduce |
Q2 2025 — 17 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 48.59K | $585.57K | 0.00% | Add | |
| 12.71K | $153.15K | 0.00% | Add | |
| 3.28K | $39.55K | 0.00% | New | |
| 1.92K | $23.10K | 0.00% | New | |
| 500 | $6.03K | 0.00% | Reduce | |
| 430 | $5.18K | 0.00% | Reduce | |
| 326 | $3.93K | 0.00% | Reduce | |
| 172 | $1.80K | 0.00% | Hold | |
| 136 | $1.64K | 0.00% | New | |
| 100 | $1.21K | 0.00% | Hold | |
| 100 | $1.21K | 0.00% | New | |
| 35 | $422 | 0.00% | Hold | |
| 30 | $362 | 0.00% | Hold | |
| 25 | $301 | 0.00% | Hold | |
| 20 | $241 | 0.00% | Hold | |
| 14 | $169 | 0.00% | Add | |
| 5 | $60 | 0.00% | Hold |
New Positions (Q3 2026)
- COURIER CAPITAL LLC 39.67K sh · $42.85K
- Vectors Research Management, LLC 19.84K sh · $21.42K
- JANE STREET GROUP, LLC 13.72K sh · $14.82K
- Squarepoint Ops LLC 12.36K sh · $13.35K
- XTX Topco Ltd 10.10K sh · $10.91K
- Nuveen, LLC 7.24K sh · $7.89K
- JONES FINANCIAL COMPANIES LLLP 200 sh · $230
Fully Exited (vs previous quarter)
- GEODE CAPITAL MANAGEMENT, LLC sold 19.02K sh · $63.54K
- Clearstead Advisors, LLC sold 650 sh · $2.17K
- Integrated Wealth Concepts LLC sold 86 sh · $287
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COURIER CAPITAL LLC | 39.67K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| HRT FINANCIAL LP | 35.38K | 29.05K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Vectors Research Management, LLC | 19.84K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Geode Capital Management | 18.96K | 19.02K | 21.63K | 14.53K | 12.71K | 12.71K | 12.09K | 10.55K | — | 61.55K | 42.87K | 38.74K | 38.74K | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 16.86K | 50.14K | 45.20K | — | — | — | — | — | — | — | — | — | — | — | — |
| JANE STREET GROUP, LLC | 13.72K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Squarepoint Ops LLC | 12.36K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| XTX Topco Ltd | 10.10K | — | — | — | — | — | — | — | — | — | 19.74K | — | — | — | — |
| VANGUARD FIDUCIARY TRUST CO | 8.31K | 8.31K | 8.31K | — | — | — | — | — | — | — | — | — | — | — | — |
| Nuveen, LLC | 7.24K | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| UBS Group AG | 5.86K | 1.11K | 3 | 1.04K | 35 | 326 | 8.45K | 2.17K | — | — | — | — | 135 | 4 | 230 |
| Tower Research Capital LLC (TRC) | 4.63K | 1.28K | 393 | 532 | — | 136 | — | 368 | — | 9.67K | 9.52K | 8.49K | 8.47K | — | — |
| BARCLAYS PLC | 3.89K | 93 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| CoreCap Advisors, LLC | 2.97K | 1.28K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Grove Bank & Trust | 1.00K | 1.00K | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Morgan Stanley | 704 | 706 | 100 | 1.08K | 880 | 430 | 1.13K | 1.15K | — | — | — | — | — | — | — |
| Quest 10 Wealth Builders, Inc. | 380 | 380 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| OSAIC HOLDINGS, INC. | 300 | 300 | 300 | 500 | 500 | 500 | 1.50K | 500 | — | — | — | — | — | — | — |
| JONES FINANCIAL COMPANIES LLLP | 200 | — | — | — | 172 | 172 | 172 | — | — | — | — | — | — | — | — |
| Rockefeller Capital Management L.P. | 150 | 150 | 150 | 300 | 300 | — | — | — | — | — | — | — | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold CVKD?
As of 2026-Q3, 26 institutional funds reported holding CVKD (CADRENAL THERAPEUTICS INC) in SEC 13F filings, with a combined reported value of $218.91K.
How many shares of CVKD do institutions own?
13F filers reported 202.81K shares of CVKD, worth $218.91K in aggregate at the end of 2026-Q3.
Is institutional ownership of CVKD rising or falling?
Share counts moved -11.9% versus the prior quarter — distribution.
Who are the top institutional holders of CVKD?
The largest 13F holders are ARMISTICE CAPITAL, LLC, Vanguard Group, Citadel Advisors, LPL Financial LLC, GEODE CAPITAL MANAGEMENT, LLC; the top 25 are ranked at the top of this page.
Who are the major shareholders of CADRENAL THERAPEUTICS INC?
The major shareholders of CADRENAL THERAPEUTICS INC (CVKD) by reported 13F value are ARMISTICE CAPITAL, LLC, Vanguard Group, Citadel Advisors, LPL Financial LLC, GEODE CAPITAL MANAGEMENT, LLC, among 51 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.